DE602004014772D1 - Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors - Google Patents
Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptorsInfo
- Publication number
- DE602004014772D1 DE602004014772D1 DE602004014772T DE602004014772T DE602004014772D1 DE 602004014772 D1 DE602004014772 D1 DE 602004014772D1 DE 602004014772 T DE602004014772 T DE 602004014772T DE 602004014772 T DE602004014772 T DE 602004014772T DE 602004014772 D1 DE602004014772 D1 DE 602004014772D1
- Authority
- DE
- Germany
- Prior art keywords
- dithion
- pyrrol
- modulators
- liver
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0316237.7A GB0316237D0 (en) | 2003-07-11 | 2003-07-11 | Therapeutic agents |
| PCT/SE2004/001115 WO2005005416A1 (en) | 2003-07-11 | 2004-07-08 | Pyrrole-2, 5-dithione derivatives as liver x receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004014772D1 true DE602004014772D1 (de) | 2008-08-14 |
Family
ID=27741986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004014772T Expired - Fee Related DE602004014772D1 (de) | 2003-07-11 | 2004-07-08 | Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20060189663A1 (de) |
| EP (1) | EP1646625B1 (de) |
| JP (1) | JP2007521313A (de) |
| KR (1) | KR20060034284A (de) |
| CN (1) | CN100478340C (de) |
| AR (1) | AR045720A1 (de) |
| AT (1) | ATE399776T1 (de) |
| AU (1) | AU2004256000B2 (de) |
| BR (1) | BRPI0412479A (de) |
| CA (1) | CA2532068A1 (de) |
| CO (1) | CO5640134A2 (de) |
| DE (1) | DE602004014772D1 (de) |
| ES (1) | ES2308205T3 (de) |
| GB (1) | GB0316237D0 (de) |
| HK (1) | HK1088318A1 (de) |
| IL (1) | IL172759A0 (de) |
| IS (1) | IS8291A (de) |
| MX (1) | MXPA06000447A (de) |
| NO (1) | NO20060080L (de) |
| RU (1) | RU2006102129A (de) |
| SA (1) | SA04250203B1 (de) |
| TW (1) | TW200507836A (de) |
| UA (1) | UA82108C2 (de) |
| UY (1) | UY28407A1 (de) |
| WO (1) | WO2005005416A1 (de) |
| ZA (1) | ZA200600229B (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0500055D0 (sv) | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
| JP2008526841A (ja) | 2005-01-10 | 2008-07-24 | アストラゼネカ アクチボラグ | 肝臓ｘ受容体調節因子としてのイソチアゾール−３（２ｈ）−オン１，１−ジオキシドのアニリン系誘導体 |
| SE0500058D0 (sv) * | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 5 |
| JP4936476B2 (ja) * | 2005-06-28 | 2012-05-23 | 第一三共株式会社 | Ｌｘｒリガンドの試験方法 |
| WO2008024724A1 (en) | 2006-08-21 | 2008-02-28 | Genentech, Inc. | Aza-benzothiophenyl compounds and methods of use |
| US10004703B2 (en) | 2006-10-12 | 2018-06-26 | Biogen Chesapeake Llc | Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels |
| US20100056444A1 (en) * | 2006-10-12 | 2010-03-04 | Sven Martin Jacobson | Treatment of Alzheimer's Disease Using Compounds that Reduce the Activity of Non Selective Ca Activated ATP- Sensitive Cation Channels Regulated by SUR1 Receptors |
| WO2008103818A1 (en) * | 2007-02-21 | 2008-08-28 | University Of Louisville Research Foundation | Therapeutic cotinine compositions |
| PT2868315T (pt) * | 2007-12-04 | 2017-09-04 | Remedy Pharmaceuticals Inc | Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos |
| US20110034560A1 (en) | 2008-01-29 | 2011-02-10 | Sven Jacobson | Liquid formulations of compounds active at sulfonylurea receptors |
| MX2010014565A (es) | 2008-07-01 | 2011-03-04 | Genentech Inc | Isoindolona y metodos de uso. |
| US8841462B2 (en) | 2008-07-01 | 2014-09-23 | Robert A. Heald | Bicyclic heterocycles as MEK kinase inhibitors |
| US20130274212A1 (en) | 2010-09-07 | 2013-10-17 | Snu R&Db Foundation | Sesterterpene Compounds and Use Thereof |
| EP3091970B1 (de) | 2014-01-10 | 2020-10-28 | Rgenix, Inc. | Lxr-agonisten und verwendungen davon |
| EP3402477A4 (de) | 2016-01-11 | 2019-08-21 | The Rockefeller University | Verfahren zur behandlung von erkrankungen im zusammenhang mit aus myeloid abgeleiteten suppressorzellen |
| CA3078981A1 (en) | 2017-11-21 | 2019-05-31 | Rgenix, Inc. | Polymorphs and uses thereof |
| KR200492570Y1 (ko) | 2018-12-04 | 2020-11-05 | 박규환 | 조립식 계단장치를 위한 발판 |
| WO2021119397A1 (en) | 2019-12-13 | 2021-06-17 | Rgenix, Inc. | Metal salts and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1119548B1 (de) * | 1998-10-08 | 2004-12-08 | SmithKline Beecham plc | 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3) |
| AU6074700A (en) * | 1999-07-08 | 2001-01-30 | Tularik Inc. | Compositions and methods for raising hdl cholesterol levels |
-
2003
- 2003-07-11 GB GBGB0316237.7A patent/GB0316237D0/en not_active Ceased
-
2004
- 2004-06-29 TW TW093119119A patent/TW200507836A/zh unknown
- 2004-07-05 SA SA4250203A patent/SA04250203B1/ar unknown
- 2004-07-08 CA CA002532068A patent/CA2532068A1/en not_active Abandoned
- 2004-07-08 KR KR1020067000616A patent/KR20060034284A/ko not_active Application Discontinuation
- 2004-07-08 RU RU2006102129/04A patent/RU2006102129A/ru not_active Application Discontinuation
- 2004-07-08 WO PCT/SE2004/001115 patent/WO2005005416A1/en active IP Right Grant
- 2004-07-08 MX MXPA06000447A patent/MXPA06000447A/es not_active Application Discontinuation
- 2004-07-08 ES ES04749151T patent/ES2308205T3/es active Active
- 2004-07-08 CN CNB2004800197194A patent/CN100478340C/zh not_active Expired - Fee Related
- 2004-07-08 US US10/563,676 patent/US20060189663A1/en not_active Abandoned
- 2004-07-08 AT AT04749151T patent/ATE399776T1/de not_active IP Right Cessation
- 2004-07-08 JP JP2006520139A patent/JP2007521313A/ja not_active Withdrawn
- 2004-07-08 AU AU2004256000A patent/AU2004256000B2/en not_active Ceased
- 2004-07-08 BR BRPI0412479-0A patent/BRPI0412479A/pt not_active IP Right Cessation
- 2004-07-08 EP EP04749151A patent/EP1646625B1/de active Active
- 2004-07-08 DE DE602004014772T patent/DE602004014772D1/de not_active Expired - Fee Related
- 2004-07-08 AR ARP040102418A patent/AR045720A1/es not_active Application Discontinuation
- 2004-07-09 UY UY28407A patent/UY28407A1/es unknown
- 2004-08-07 UA UAA200600270A patent/UA82108C2/uk unknown
-
2005
- 2005-12-22 IL IL172759A patent/IL172759A0/en unknown
-
2006
- 2006-01-05 NO NO20060080A patent/NO20060080L/no not_active Application Discontinuation
- 2006-01-10 ZA ZA200600229A patent/ZA200600229B/xx unknown
- 2006-01-20 CO CO06005238A patent/CO5640134A2/es not_active Application Discontinuation
- 2006-02-09 IS IS8291A patent/IS8291A/is unknown
- 2006-08-07 HK HK06108722.2A patent/HK1088318A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IS8291A (is) | 2006-02-09 |
| IL172759A0 (en) | 2006-04-10 |
| KR20060034284A (ko) | 2006-04-21 |
| TW200507836A (en) | 2005-03-01 |
| BRPI0412479A (pt) | 2006-09-19 |
| SA04250203B1 (ar) | 2008-02-25 |
| CO5640134A2 (es) | 2006-05-31 |
| EP1646625B1 (de) | 2008-07-02 |
| HK1088318A1 (en) | 2006-11-03 |
| UY28407A1 (es) | 2005-02-28 |
| ZA200600229B (en) | 2007-04-25 |
| CA2532068A1 (en) | 2005-01-20 |
| GB0316237D0 (en) | 2003-08-13 |
| NO20060080L (no) | 2006-02-08 |
| US20060189663A1 (en) | 2006-08-24 |
| UA82108C2 (uk) | 2008-03-11 |
| RU2006102129A (ru) | 2006-08-27 |
| JP2007521313A (ja) | 2007-08-02 |
| MXPA06000447A (es) | 2006-04-07 |
| AU2004256000A1 (en) | 2005-01-20 |
| ES2308205T3 (es) | 2008-12-01 |
| EP1646625A1 (de) | 2006-04-19 |
| CN100478340C (zh) | 2009-04-15 |
| ATE399776T1 (de) | 2008-07-15 |
| AR045720A1 (es) | 2005-11-09 |
| CN1820003A (zh) | 2006-08-16 |
| AU2004256000B2 (en) | 2007-07-26 |
| WO2005005416A1 (en) | 2005-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTPA2017005I1 (lt) | Nauji junginiai, kaip opioido receptoriaus moduliatoriai | |
| ATE497953T1 (de) | Thiazolderivate als modulatoren des cannabinoidrezeptors | |
| ATE451364T1 (de) | Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate | |
| ATE440085T1 (de) | 3-substituierte 1,5-diphenylpyrazolderivate, die sich als cb1-modulatoren eignen | |
| PT1444215E (pt) | Derivados de 1,2,4-triadiazolio como moduladores do receptor de melanocortina | |
| DK1833799T3 (da) | 3-phenyl-pyrazol derivater, som modulatorer af 5-HT-2a-serotonin receptor nyttig til behandlingen af sygdomme relateret hertil | |
| ATE439357T1 (de) | Indolylderivate als liver-x-rezeptormodulatoren | |
| DE602005027307D1 (de) | Arylanilinderivate als agonisten des beta2-adrenergen rezeptors | |
| MA28391B1 (fr) | Dérivés de 3-cycloalkylaminopyrrolidine utiles comme modulateurs de récepteurs de chimiokines | |
| DE602004015724D1 (de) | Diazepinoindolderivate als kinaseinhibitoren | |
| NO20051042L (no) | Pyrimidylsulfonamidderivater som kemokinreseptormodulatorer | |
| DE60325025D1 (de) | Modulatoren des vanilloidrezeptors | |
| DE602004024420D1 (de) | Chinazolinderivate als antitumormittel | |
| DK1668014T3 (da) | Kondenserede heterocykliske forbindelser som serotoninreceptormodulatorer | |
| IL172759A0 (en) | Pyrrole-2,5-dithione derivatives as liver x receptor modulators | |
| IL172760A0 (en) | Pyrrole-2,5-dithione derivatives as liver x receptor modulators | |
| DE60305903D1 (de) | Tropanderivative als ccr5-modulatoren | |
| ZA200609234B (en) | Substituted azeplne derivatives as serotonin receptor modulators | |
| AU2003256922A8 (en) | Substituted heterocyclic compounds as modulators of the ccr5 receptor | |
| DE602004007387D1 (de) | 5-substituierte chinazolinonderivate | |
| ATE394372T1 (de) | G-lactamderivate als prostaglandinagonisten | |
| DE602004012555D1 (de) | Benzothiazol-derivate als liganden des adenosinrezeptors | |
| FR2878980B1 (fr) | Unite de retro-eclairage de type direct. | |
| ATE398620T1 (de) | Spirokondensierte indolinderivate als pestizide | |
| DE602004009583D1 (de) | Piperidin- oder 8-azabicycloä3.2.1üoct-3-ylderivate, die sich als modulatoren der chemokinrezeptoraktivität eignen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |